Natco Pharma receives EIR from US FDA for Visakhapatnam manufacturing plant


The shares of NATCO Pharma gained on Friday, November 20, after the company announced that it had been issued an EIR (Establishment Inspection Report) from the US Food and Drug Administration.

The company said that it had received the EIR from the US FDA for its manufacturing plant located in Parawada, Visakhapatnam, according to a regulatory filing on Friday.

What is an EIR?

An EIR is an official document issued by the US FDA that records the findings of an inspection at a regulated facility, such as a pharmaceutical or medical device manufacturing plant.

The EIR builds on the Form 483 issued in August

The USFDA inspected the company’s finished dosage form (FDF) manufacturing facility from August 17 to 21 this year as it had reported in a separated exchange filing in August.

Back then, it said that it had been issued four observations in Form 483. The latest EIR classifies the inspection as Voluntary Action Indicated (VAI), the present filing notes.

A VAI indicates that the FDA found issues during an inspection but does not plan to take regulatory action, provided the company addresses them.

What is a Form 483?

A Form 483 lists observations made by US FDA inspectors during a facility inspection. It is shared with the company at the closing meeting but does not represent the FDA’s final assessment of its compliance with manufacturing standards.

The company is generally given 15 days to respond, outlining how it plans to address the observations.

How did the company fare in Q2?

Natco Pharma reported a weak performance in the September quarter of FY27, with revenue, net profit and operating earnings declining year-on-year.

Revenue fell 29% to ₹967.3 crore from ₹1,363 crore in Q2FY26, while net profit dropped 60.9% to ₹202.6 crore from ₹518.4 crore.

Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) declined 55.4% to ₹258 crore from ₹579 crore, while the EBITDA margin contracted by 1,590 basis points to 26.6% from 42.5% a year earlier.

Market reaction

The shares of Natco Pharma gained as high as 1.17% on Friday, extending its gains for the second straight day, before paring its gains to trade in the red at 0.59% lower as of 12.39 pm.

The stock has registered losses of 7.25% in the year-to-date period, with additional losses of 5.23% in the trailing 12-month period.

Home/Market News/

Natco Pharma receives EIR from US FDA for Visakhapatnam manufacturing plant



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *